Neuroblastoma Market Trends

Growth Drivers

• Enhanced Survival Rates of Children Diagnosed with Neuroblastoma - For instance, a 5-year relative survival rate of more than 95% is achieved by children with low-risk neuroblastoma, and between 90% and 95% is achieved by children with intermediate-risk neuroblastoma. In children with neuroblastoma at high risk, the 5-year relative survival rate is approximately 50%. Since the introduction of effective treatments and therapies, the survival rate of children diagnosed with neuroblastoma has increased significantly. This has resulted in increased demand for treatments and therapies, driving growth in the neuroblastoma market.
• Support And Funding from The Government for Children With Cancer- For instance, Lions Clubs International Foundation (LCIF) provides grants to projects that address the needs of children with cancer and their families. This can include financial assistance for medical costs, educational opportunities, and other supportive services. LCIF also works to increase public awareness of the needs of children with cancer and the importance of early detection and treatment of the disease.
• Increasing Expenditures on Cancer Treatment- A significant proportion of U.S. healthcare expenditures is spent on cancer. Oncology health care in the U.S. is expected to grow to USD 246 billion by 2030, which is an increase of 34% over the 2015 amount of USD 183 billion spent in the U.S. on cancer health care.
• Pharmacological Study of Targeted Drugs for Treating Neuroblastoma - There are now clinical trials examining new drugs targeting neuroblastoma cells more specifically than standard chemotherapy drugs. For instance, Crizotinib (Xalkori) is being studied for treating children with high-risk neuroblastoma when their cells display abnormal ALK gene sequences. In addition to lorlatinib (Lorbrena) and ceritinib (Zykadia), other drugs that target ALK-reactive cells are also being explored.
• Drug Approvals by Regulatory Authorities For Cancer Treatment - For instance, on November 25, 2020, Naxitamab (Danyelza) has been approved by the US Food and Drug Administration (FDA) for the treatment of high-risk neuroblastoma cases. Research at Memorial Sloan Kettering's MSK Kids program contributed to the development of naxitamab (Danyelza).

Challenges

• Side effects associated with the treatments - Neuroblastoma treatments are often very harsh, with long-term effects on the patient's physical and mental health. These side effects can range from nausea and fatigue to memory loss and cognitive impairment, which can all have a negative impact on quality of life.
• Lack of awareness about the condition and its symptoms
• High cost of treatment and limited access to advanced therapies in developing economies